People
Alexandra Cantley
Polaris Partners partner focused on early-stage biotechnology and healthcare. Previously conducted research at Inzen Therapeutics and Vertex; holds a Harvard chemical biology doctorate. TRexBio director as of October 5, 2026, with resignation planned immediately before IPO registration effectiveness. BeMe’s2021issuer announcement names her among its board members and advisors. That collective description does not assign an individual director seat; recorded affiliation remains qualified and historical after acquisition. Polaris managing partner in New York, focused on early biotechnology and healthcare investing. Joined in2019. Her current manager biography includes boards of EpiBiologics, TRexBio, Auron, Amplifire and SunBird Bio; older company affiliations retain their own date qualifications.
Roles
Board Member
Founding Investor Director (published2021; historical)
Managing Partner
Board Observer
Managing Partner